Displaying 135 (all) recruiting clinical trials.
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer
We are conducting a clinical trial to test a new combination of four drugs for treating pancreatic cancer. Our research in the lab has shown ...
-
A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma
This study wants to find out if a new treatment called V940, when used with pembrolizumab, has fewer side effects and is more effective than ...
-
A first-in-human Phase I non-randomized open-label multicentre dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by repeated intravenous infusions in patients with malignant solid tumors expressing B7-H6
This study is testing different doses of a dtreatment called BI 765049, either alone or with another drug called ezabenlimab for patients with tumors expressing ...
-
A Phase 2 Open-Label Multi-Center Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible fo
This study looks at two treatments (TAR-200 + IV cetrelimab versus IV cetrelimab alone) for a specific kind of bladder cancer (muscle-invasive bladder cancer unsuitable for ...
-
A Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Antitumor Activity of TNG348 Single Agent and in Combination with a PARP Inhibitor in Patients with BRCA 1/2 Mutant or Other HRD+ Advanced or Metastatic S
This study is split into two parts: Phase 1 and Phase 2. The study team is testing a new medicine, TNG348, for patients with tumors ...